ALK and anaplastic large cell lymphoma: In the pursuit of enhanced precision, the novel folate-guided degrader was constructed for targeted delivery to reduce off-target toxicity.404 Crizotinib is the only ALK inhibitor approved in R/R ALCL patients with ALK-positive status.